Vernal Keratoconjunctivitis When Corticosteroids, Cyclosporine, or Antiallergy Medications Have Not Worked

Vernal keratoconjunctivitis (VKC) is a recurrent, chronic inflammatory condition of the ocular surface that can prove refractory to standard therapies. When disease activity persists despite conventional treatment, a defined escalation approach is available.

Clinical Situation

This protocol targets patients with VKC whose condition has not responded adequately to topical corticosteroids, cyclosporine, and/or antiallergy medications — a subset in whom continued conventional management is insufficient and a structured next step is warranted.

Treatment Approach

The protocol involves a specific calcineurin inhibitor agent — tacrolimus — used in patients who have not achieved satisfactory disease control with standard conjunctivitis therapies. The complete regimen, including dosing parameters and clinical sequencing, is available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Randomized clinical trials have demonstrated the efficacy of topical tacrolimus 0.1% applied conjunctivally in patients who had failed conjunctivitis therapy with topical corticosteroids, cyclosporine, and/or antiallergy medications.

View source ↗